A New Weapon in the Fight Against Disease | Science

A New Weapon in the Fight Against Disease | Science

The research has two modern points: the invention of a brand new therapeutic goal and the event of an efficient nanocarrier for the selective supply of immunotherapy and chemotherapy medication.

Researchers have developed cancer-fighting nanoparticles that may ship modern chemoimmunotherapy.

In keeping with a brand new research printed within the journal Nature Nanotechnology, researchers on the College of Pittsburgh have developed cancer-fighting nanoparticles that concurrently ship chemotherapy and a novel immunotherapy.

The brand new immunotherapy, which silences a gene concerned in immunosuppression, has been proven to be efficient in shrinking tumors in mouse fashions of colon and pancreatic most cancers when mixed with chemotherapy and packaged into nanoparticles.

“There are two modern points of our research: the invention of a brand new therapeutic goal and a brand new nanocarrier that could be very efficient in selective supply of immunotherapy and chemotherapeutic medication,” stated senior creator Music Li, M.D., Ph.D., professor of pharmaceutical sciences within the Pitt Faculty of Pharmacy and UPMC Hillman Most cancers Middle investigator. “I’m enthusiastic about this analysis as a result of it’s extremely translational. We don’t know but whether or not our method works in sufferers, however our findings counsel that there’s a lot of potential.”

FuOXP siRNA Nanoparticles

Electron microscopy picture of nanoparticles containing the chemotherapy drug FuOXP and novel immunotherapy of siRNA that blocks expression of Xkr8. Credit score: Chen et al., 2022, Nature Nanotechnology, 10.1038/s41565-022-01266-2

Chemotherapy is a pillar of most cancers remedy, however residual most cancers cells can persist and trigger tumor relapse. This course of entails a lipid referred to as phosphatidylserine (PS), which is often discovered contained in the tumor cell membrane’s interior layer however migrates to the cell floor in response to chemotherapy medication. On the floor, PS acts as an immunosuppressant, defending the remaining most cancers cells from the immune system.

The Pitt researchers discovered that remedy with chemotherapy medication fluorouracil and oxoplatin (FuOXP)

led to elevated ranges of Xkr8, a protein that controls the distribution of PS on the cell membrane. This discovering steered that blocking Xkr8 would forestall most cancers cells from shunting PS to the cell floor, permitting immune cells to mop up most cancers cells that lingered after chemotherapy.

Proposed Strategy for FuOXP Mediated Immunosuppression and Effect of Xkr8 siRNA

Proposed technique for a way chemotherapy FuOXP can result in immunosuppression (left facet of picture) in tumors however a novel immunotherapy that blocks expression of a protein referred to as Xkr8 can reactivate the immune system (proper facet of picture). The brand new research discovered that FuOXP led to elevated ranges of Xkr8, a protein that redistributes PS to the cell floor, leading to immunosuppression as a result of extra T-regulatory cells and tumor-promoting M2 macrophages. Nonetheless, when the researchers blocked the expression of Xkr8 with siRNA, PS remained throughout the cell membrane’s interior layer, enhancing the immune system by boosting the numbers of tumor-fighting T cells, M1 macrophages, and dendritic cells. Credit score: Chen et al., 2022, Nature Nanotechnology, 10.1038/s41565-022-01266-2

In an unbiased research that was not too long ago printed in Cell Reports, Yi-Nan Gong, Ph.D., assistant professor of immunology at Pitt, also identified Xkr8 as a novel therapeutic target to boost anti-tumor immune response.

Li and his team designed snippets of genetic code called short interference RNA (siRNA), which shuts down the production of specific proteins — in this case, Xkr8. After packaging siRNA and FuOXP together into dual-action nanoparticles, the next step was targeting them to tumors.

Song Li

Song Li, M.D., Ph.D., professor of pharmaceutical sciences in the Pitt School of Pharmacy and UPMC Hillman Cancer Center investigator. Credit: Jan Shaw

Nanoparticles are typically too large to cross intact blood vessels in healthy tissue, but they can reach cancer cells because tumors sometimes have poorly developed vessels with holes that allow them passage. But this tumor-targeting approach is limited because many human tumors do not have large enough holes for nanoparticles to pass through.

“Like a ferry carrying people from one side of the river to the other, we wanted to develop a mechanism that allows nanoparticles to cross intact blood vessels without relying on holes,” said Li.

To develop such a ferry, the researchers decorated the surface of the nanoparticles with chondroitin sulfate and PEG. These compounds help the nanoparticles target tumors and avoid healthy tissue by binding to cell receptors common on both tumor blood vessels and tumor cells and prolonging the length of time they remain in the bloodstream.

FuOXP siRNA Nanoparticles and Mouse Colon Cancer Cells

Fluorescence microscopy image showing FuOXP-siRNA nanoparticles (red) effectively taken up by mouse colon cancer cells. Cell nuclei appear as blue circles. Credit: Chen et al., 2022, Nature Nanotechnology, 10.1038/s41565-022-01266-2

When injected into mice, about 10% of the nanoparticles made their way to their tumor — a significant improvement over most other nanocarrier platforms. A previous analysis of published research found that, on average, only 0.7% of nanoparticle doses reach their target.

The dual-action nanoparticles dramatically reduced the migration of immunosuppressing PS to the cell surface compared to nanoparticles containing the chemodrug FuOXP alone.

Next, the researchers tested their platform in mouse models of colon and pancreatic cancer. Animals treated with nanoparticles containing both FuOXP and siRNA had better tumor microenvironments with more cancer-fighting T cells and fewer immunosuppressive regulatory T cells than animals that received placebo or FuOXP doses.

As a result, mice that received the siRNA-FuOXP nanoparticles showed a dramatic decrease in tumor size compared to animals that received those carrying just one therapy.

According to Li, the study also pointed to the potential of combining the FuOXP-siRNA nanoparticles with another type of immunotherapy called checkpoint inhibitors. Immune checkpoints such as PD-1 act like brakes on the immune system, but checkpoint inhibitors work to release the brakes and help immune cells to fight cancer.

The researchers found that FuOXP nanoparticles with or without siRNA increased PD-1 expression. But when they added a PD-1 inhibitor drug, the combination therapy had drastic improvements in tumor growth and survival in mice.

With their sights set on translating their novel therapy to the clinic, the team is now looking to validate their findings with additional experiments and further evaluate potential side effects.

References: “Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy” by Yuang Chen, Yixian Huang, Qinzhe Li, Zhangyi Luo, Ziqian Zhang, Haozhe Huang, Jingjing Sun, LinXinTian Zhang, Runzi Sun, Daniel J. Bain, James F. Conway, Binfeng Lu and Song Li, 24 November 2022, Nature Nanotechnology.
DOI: 10.1038/s41565-022-01266-2

“Mobilizing phospholipids on tumor plasma membrane implicates phosphatidylserine externalization blockade for cancer immunotherapy” by Weihong Wang, Shaoxian Wu, Zhanpeng Cen, Yixin Zhang, Yuang Chen, Yixian Huang, Anthony R. Cillo, Joshua S. Prokopec, Giovanni Quarato, Dario A.A. Vignali, Jacob Stewart-Ornstein, Song Li, Binfeng Lu and Yi-Nan Gong, 1 November 2022, Cell Reports.
DOI: 10.1016/j.celrep.2022.111582

The study was funded by the National Institutes of Health. 

Related posts

You Don’t Want To See What Comes Up When You Flush a Public Restroom Toilet | Science


The Mysterious Case of the Disappearing White-Lipped Peccaries | Science


Good News That Inspires Some Hope For Climate Change


Leave a Comment